3 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 122 points (0.7%) at 17,066 as of Monday, July 14, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,069 issues advancing vs. 930 declining with 155 unchanged.

The Drugs industry currently sits up 1.5% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Perrigo ( PRGO), up 5.9%, Mylan ( MYL), up 2.7%, Grifols ( GRFS), up 2.4%, Shire ( SHPG), up 1.9% and Novartis ( NVS), up 0.8%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.43 (1.0%) to $41.73 on average volume. Thus far, 3.5 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $41.50-$41.95 after having opened the day at $41.95 as compared to the previous trading day's close of $41.30.

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $61.9 billion and is part of the health care sector. Shares are up 7.8% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and weak operating cash flow. Get the full Abbott Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.34 (0.6%) to $54.80 on average volume. Thus far, 1.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.8 million shares. The stock has ranged in price between $54.36-$55.04 after having opened the day at $54.74 as compared to the previous trading day's close of $54.46.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $46.0 billion and is part of the health care sector. Shares are up 35.9% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.24 (1.4%) to $89.97 on average volume. Thus far, 5.9 million shares of Gilead exchanged hands as compared to its average daily volume of 12.9 million shares. The stock has ranged in price between $88.84-$90.19 after having opened the day at $89.13 as compared to the previous trading day's close of $88.73.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $136.6 billion and is part of the health care sector. Shares are up 18.1% year-to-date as of the close of trading on Friday. Currently there are 15 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

Video: Jim Cramer on Netflix, Disney, Intel, Micron and Goldman Sachs

Video: Jim Cramer on Netflix, Disney, Intel, Micron and Goldman Sachs